276 related articles for article (PubMed ID: 23892588)
1. Evolving treatment strategies for management of carcinoid tumors.
Strosberg J
Curr Treat Options Oncol; 2013 Sep; 14(3):374-88. PubMed ID: 23892588
[TBL] [Abstract][Full Text] [Related]
2. Systemic Therapies for Advanced Gastrointestinal Carcinoid Tumors.
Mulvey CK; Bergsland EK
Hematol Oncol Clin North Am; 2016 Feb; 30(1):63-82. PubMed ID: 26614369
[TBL] [Abstract][Full Text] [Related]
3. Systemic therapy for advanced carcinoid tumors: where do we go from here?
Paulson AS; Bergsland EK
J Natl Compr Canc Netw; 2012 Jun; 10(6):785-93. PubMed ID: 22679120
[TBL] [Abstract][Full Text] [Related]
4. Systemic Therapies for Advanced Pancreatic Neuroendocrine Tumors.
Raj N; Reidy-Lagunes D
Hematol Oncol Clin North Am; 2016 Feb; 30(1):119-33. PubMed ID: 26614372
[TBL] [Abstract][Full Text] [Related]
5. Neuroendocrine tumours of the small intestine.
Strosberg J
Best Pract Res Clin Gastroenterol; 2012 Dec; 26(6):755-73. PubMed ID: 23582917
[TBL] [Abstract][Full Text] [Related]
6. Advances in the systemic treatment of neuroendocrine tumors in the era of molecular therapy.
Leung R; Lang B; Wong H; Chiu J; Yat WK; Shek T; Cho WY; Yau LC; Yau T
Anticancer Agents Med Chem; 2013 Mar; 13(3):382-8. PubMed ID: 23092266
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of mTOR in carcinoid tumors.
Grozinsky-Glasberg S; Pavel M
Target Oncol; 2012 Sep; 7(3):189-95. PubMed ID: 22886906
[TBL] [Abstract][Full Text] [Related]
8. Digestive neuroendocrine tumors (DNET): the era of targeted therapies.
Boussaha T; Rougier P; Taieb J; Lepere C
Clin Res Hepatol Gastroenterol; 2013 Apr; 37(2):134-41. PubMed ID: 23562338
[TBL] [Abstract][Full Text] [Related]
9. Effects of the single and combined treatment with dopamine agonist, somatostatin analog and mTOR inhibitors in a human lung carcinoid cell line: an in vitro study.
Pivonello C; Rousaki P; Negri M; Sarnataro M; Napolitano M; Marino FZ; Patalano R; De Martino MC; Sciammarella C; Faggiano A; Rocco G; Franco R; Kaltsas GA; Colao A; Pivonello R
Endocrine; 2017 Jun; 56(3):603-620. PubMed ID: 27688013
[TBL] [Abstract][Full Text] [Related]
10. Somatostatin receptor subtypes in human non-functioning neuroendocrine tumors and effects of somatostatin analogue SOM230 on cell proliferation in cell line NCI-H727.
Ono K; Suzuki T; Miki Y; Taniyama Y; Nakamura Y; Noda Y; Watanabe M; Sasano H
Anticancer Res; 2007; 27(4B):2231-9. PubMed ID: 17695508
[TBL] [Abstract][Full Text] [Related]
11. [Medical treatment of digestive neuroendocrine tumours].
Panzuto F; Nasoni S; Delle Fave G
Minerva Endocrinol; 2001 Sep; 26(3):145-8. PubMed ID: 11753237
[TBL] [Abstract][Full Text] [Related]
12. Antiproliferative effect of somatostatin analogs in gastroenteropancreatic neuroendocrine tumors.
Strosberg J; Kvols L
World J Gastroenterol; 2010 Jun; 16(24):2963-70. PubMed ID: 20572298
[TBL] [Abstract][Full Text] [Related]
13. [Carcinoid tumors].
Pregun I; Bodoky G; Rácz K; Tulassay Z
Orv Hetil; 2010 Nov; 151(46):1885-94. PubMed ID: 21044939
[TBL] [Abstract][Full Text] [Related]
14. Role of Somatostatin Analogues in the Treatment of Neuroendocrine Tumors.
Narayanan S; Kunz PL
Hematol Oncol Clin North Am; 2016 Feb; 30(1):163-77. PubMed ID: 26614375
[TBL] [Abstract][Full Text] [Related]
15. [Chemoembolization, immunotherapy and hormone therapy of carcinoid and digestive neuroendocrine tumors].
Gouyon B; Ruszniewski P
Ann Gastroenterol Hepatol (Paris); 1995; 31(2):121-3. PubMed ID: 7618834
[No Abstract] [Full Text] [Related]
16. Current and emerging strategies for the management of advanced/metastatic lung neuroendocrine tumors.
Rutherford M; Wheless M; Thomas K; Ramirez RA
Curr Probl Cancer; 2024 Apr; 49():101061. PubMed ID: 38281845
[TBL] [Abstract][Full Text] [Related]
17. An update of lanreotide acetate for treatment of adults with carcinoid syndrome.
Guadalupe E; Deshpande HA; Stein SM
Drugs Today (Barc); 2018 Aug; 54(8):457-465. PubMed ID: 30209440
[TBL] [Abstract][Full Text] [Related]
18. [Somatostatin analogs].
Krysiak R; Okopień B; Herman ZS
Pol Arch Med Wewn; 2006 Oct; 116(4):988-97. PubMed ID: 18416302
[No Abstract] [Full Text] [Related]
19. Current clinical trials of targeted agents for well-differentiated neuroendocrine tumors.
Raj N; Reidy-Lagunes D
Pancreas; 2014 Nov; 43(8):1185-9. PubMed ID: 25333401
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of Peripheral Synthesis of Serotonin as a New Target in Neuroendocrine Tumors.
Molina-Cerrillo J; Alonso-Gordoa T; Martínez-Sáez O; Grande E
Oncologist; 2016 Jun; 21(6):701-7. PubMed ID: 27107003
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
